| pubmed-article:19822302 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0376545 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0184511 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0026565 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0040739 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0441994 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C1521828 | lld:lifeskim |
| pubmed-article:19822302 | lifeskim:mentions | umls-concept:C0003442 | lld:lifeskim |
| pubmed-article:19822302 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:19822302 | pubmed:dateCreated | 2009-10-13 | lld:pubmed |
| pubmed-article:19822302 | pubmed:abstractText | We sought to reduce the risk of infectious complications and nonrelapse mortality (NRM) associated with the use of antithymocyte globulin (ATG) without compromising control of acute graft-versus-host disease (aGVHD) in patients undergoing reduced-intensity conditioning (RIC) transplantation. As part of an ongoing quality improvement effort, we lowered the dose of rabbit ATG from 7.5 mg/kg of ATG (R-ATG) (n = 39) to 6.0 mg/kg of ATG (r-ATG) (n = 33) in association with fludarabine (Flu) and busulfan (BU) RIC transplantation and then monitored patients for adverse events, relapse, and survival. Of the 72 mostly high risk (82%) patients studied, 89% received unrelated donor allografts, 25% of which were HLA-mismatched. No differences in posttransplantation full donor-cell chimerism rates were observed between the 2 ATG-dose groups (P > .05). When R-ATG versus r-ATG patients were compared, we observed no significant difference in the cumulative incidence of grade II-IV aGVHD (32% versus 27%; P = .73) or grade III-IV aGVHD (23% versus 11%; P = .28). However, the r-ATG group had significantly less cytomegalovirus (CMV) reactivation (64% versus 30%; P = .005) and bacterial infections (56% versus 18%; P = .001), a better 1-year cumulative incidence of NRM (18% versus 3%; P = .03), and a trend for better 1-year overall survival (OS) (64% versus 84%; P = .07) compared to R-ATG patients. A seemingly modest reduction in the dose of rabbit ATG did not compromise control of aGVHD or achievement of donor chimerism, but led to a significant decrease in the risk of serious infections and NRM in high-risk RIC allograft recipients. | lld:pubmed |
| pubmed-article:19822302 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19822302 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19822302 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19822302 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19822302 | pubmed:issn | 1523-6536 | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:ByrdJohn CJC | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:PhillipsGaryG | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:GarzonRamiroR | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:DevineSteven... | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:MarcucciGuido... | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:AndritsosLesl... | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:BlumWilliamW | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:LinThomasT | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:BechtelThomas... | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:BensonDon MDM | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:HamadaniMehdi... | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:ElderPatrickP | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:PenzaSamS | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:KlisovicRebec... | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:O'DonnellLynn... | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:HofmeisterCra... | lld:pubmed |
| pubmed-article:19822302 | pubmed:author | pubmed-author:KrughDavidD | lld:pubmed |
| pubmed-article:19822302 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19822302 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:19822302 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19822302 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19822302 | pubmed:pagination | 1422-30 | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:meshHeading | pubmed-meshheading:19822302... | lld:pubmed |
| pubmed-article:19822302 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19822302 | pubmed:articleTitle | Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. | lld:pubmed |
| pubmed-article:19822302 | pubmed:affiliation | Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA. mehdi.hamadani@gmail.com | lld:pubmed |
| pubmed-article:19822302 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19822302 | pubmed:publicationType | Clinical Trial | lld:pubmed |
